Kynurenic Acid

Urinary kynurenic acid reflects both how your body produces this compound and how your kidneys handle it. Researchers have found associations with depressive symptoms, bowel disorders, and kidney disease, but a urine result cannot identify which of these processes explains your number.

This is an exploratory marker. There are no validated urinary targets for mood, memory, or longevity, and studies haven't established that choosing treatment according to this number improves those outcomes.

Where It Comes From

Your body needs tryptophan to build proteins and gets it from food. Most tryptophan breakdown takes place through a series of reactions called the kynurenine pathway. That doesn't mean nearly all the tryptophan you eat immediately enters this pathway.

One branch converts kynurenine into kynurenic acid. Other reactions produce compounds including quinolinic acid. Inflammatory signals can change the enzymes controlling these reactions, but the concentration of one product in urine doesn't reveal how much tryptophan passes through each branch.

Glutamate carries signals between nerve cells. Cell and animal experiments show that kynurenic acid can block some receptors through which glutamate activates those cells, reducing injury from excessive stimulation under certain conditions. Quinolinic acid can stimulate the same receptor system. These effects depend on concentration and location, so describing the compounds as uniformly protective or harmful oversimplifies their biology.

Kynurenic acid is produced in the brain and in tissues elsewhere in the body. The kidneys remove it through filtration and active transport into urine. Changes in kidney transport can therefore change its concentration even when its production hasn't changed.

What the Number Measures

This test measures kynurenic acid in urine using liquid chromatography with mass spectrometry, or LC-MS. The method separates compounds in the sample and identifies them by their chemical properties.

The result is reported in micrograms per gram of creatinine, written as mcg/g. Creatinine is a waste product associated with muscle metabolism. Dividing by urine creatinine reduces the effect of urine dilution, although differences in muscle mass and creatinine excretion can still affect the ratio.

This is a concentration relative to creatinine. It doesn't measure total daily production, the amount stored in your tissues, or the proportion of tryptophan taking a particular route.

Urine, Blood, and the Brain

Kynurenic acid crosses the blood-brain barrier poorly. The brain produces much of its own supply from kynurenine, which crosses more readily. A urine concentration therefore cannot be used to calculate your brain concentration.

In 30 healthy men, kynurenic acid in a 24-hour urine collection correlated moderately with plasma levels. Plasma levels did not correlate with levels in the fluid surrounding the brain and spinal cord. Larger studies have found only weak correlations between plasma and spinal-fluid levels, too weak for blood to stand in for the brain. The 30-man study measured kynurenic acid with chromatography and fluorescence detection, a different analytical method from this LC-MS test. Its findings support caution about interpreting measurements from different parts of the body as interchangeable.

Mood and Depression

In a cross-sectional study of 169 young adults, lower creatinine-adjusted urinary kynurenic acid was associated with more depressive symptoms, including after adjustment for measured inflammatory markers. Kynurenic acid was measured using chromatography with fluorescence detection. This is evidence about the same urinary compound, but it doesn't establish diagnostic performance for this LC-MS test.

Separate studies measured kynurenic acid in blood plasma. One compared 88 people with major depression with 88 healthy controls. Among the 62 people assessed after escitalopram treatment, lower baseline plasma levels were associated with greater symptom improvement. That finding hasn't established a urine-based way to choose an antidepressant.

Another small plasma study included 76 people. Within that study, kynurenic acid identified about nine in ten people with depression and correctly classified about seven in ten controls. Those estimates came from a selected research sample and cannot be applied to this urine test or assumed to hold in routine screening.

Pooled analyses of blood studies found lower kynurenic acid in current major depression, especially in people not taking medication, with levels rising after treatment. In a large population-based study, the associations were small enough to raise doubts about their usefulness for individual decisions. None of this work tested urine.

Kidney Function

Kidney function affects both circulating kynurenic acid and its appearance in urine. Filtration is only part of the explanation because kidney cells also transport the molecule into urine.

A study of 119 people compared healthy controls with people across several stages of chronic kidney disease. Its exploratory LC-MS analysis found that the urinary kynurenic acid signal separated the groups only weakly; the serum signal performed better. This was a research comparison across groups, not a validation of urinary kynurenic acid as an early kidney screening test.

There is also direct evidence from people already seriously ill with kidney injury. In an analysis of 92 intensive-care patients, higher creatinine-adjusted urinary kynurenic acid was associated with delayed or absent kidney recovery, need for dialysis, and death within 30 days. That finding illustrates why a higher urinary level cannot automatically be called beneficial. It doesn't establish how to interpret an otherwise healthy person's result.

In a separate cohort of about 2,400 people with chronic kidney disease, higher serum kynurenic acid was associated with progression to kidney failure after adjustment for other risk factors. The accompanying animal experiments explored possible mechanisms, but the human data did not establish that kynurenic acid caused the progression. The direction isn't consistent across cohorts. In people with type 2 diabetes, higher plasma kynurenic acid was associated with a lower risk of progressing to kidney failure, and a study in moderate chronic kidney disease found no clear relationship. These blood findings cannot supply a treatment target for urine.

Kidney transplant research points to another context. Recipients who maintained their transplant without ongoing immunosuppressive drugs had urinary profiles enriched in kynurenic acid. This association did not prove that the molecule produced immune tolerance, and it cannot establish whether stopping anti-rejection medication is safe.

Schizophrenia and Brain Chemistry

A pooled analysis found higher kynurenic acid in brain tissue and spinal fluid in schizophrenia, while the pooled blood findings did not show the same increase. Experimental research suggests that excessive activity within the brain can interfere with signaling involved in cognition.

These findings concern brain tissue, spinal fluid, and blood. They do not validate urinary kynurenic acid for diagnosing schizophrenia or measuring the brain processes involved.

Memory and Alzheimer's Disease

An Alzheimer's study analyzed urine from 560 people and found lower urinary kynurenic acid in groups with Alzheimer's disease or mild cognitive impairment than in controls. The researchers used relative LC-MS signals adjusted for creatinine, so their results aren't interchangeable with calibrated concentrations from this test. The serum kynurenic acid difference did not remain statistically convincing after accounting for the many comparisons made.

A later meta-analysis also found that results differed by sample type, with lower kynurenic acid in pooled blood studies and slightly higher levels in spinal-fluid studies. These associations haven't established a urine test that predicts who will develop dementia or a monitoring strategy for people with a family history.

Gut Symptoms

A study compared 40 people with constipation-predominant irritable bowel syndrome, 40 with diarrhea-predominant IBS, and 40 healthy controls. It measured urine compounds by LC-MS/MS and adjusted them for creatinine. The constipation group had lower kynurenic acid than controls, and lower levels within that group were associated with more depressive symptoms.

Those findings don't show whether the urinary change caused symptoms or followed them. They also don't establish that an individual result can identify altered gut bacteria. IBS and small intestinal bacterial overgrowth require their own diagnostic assessment.

Long-Term Outcome Studies

Some larger studies have examined kynurenic acid and mortality. The studies below measured it in blood, so they provide context about the molecule without validating this urine test for estimating lifespan.

Other disease-specific studies, including the kidney research above, have found associations with adverse outcomes. Taken together, these findings do not support a universal direction in which urinary kynurenic acid should move.

When Results Can Be Misleading

• Urine dilution and creatinine: creatinine adjustment reduces dilution effects but introduces a denominator influenced by muscle mass and creatinine excretion. A change in the reported ratio doesn't necessarily mean the same change in kynurenic acid production.
• Kidney handling: impaired filtration or altered transport into urine can change the result. A filtration estimate alone cannot determine how much of a change comes from tubular transport.
• Fasting: a small eight-day fasting study found increases in kynurenic acid in both serum and creatinine-adjusted urine. Blood studies found rises after fasts of six days and even two days, so a fast shorter than a week may matter too. None of this establishes what an ordinary overnight fast does to this test.
• Recent exercise: a randomized crossover study in 24 young men found a brief rise in serum kynurenic acid after both endurance and resistance exercise. It measured blood, so it does not establish a corresponding urinary change or a required exercise-free interval before urine collection.
• Medication: probenecid inhibits kidney transporters involved in kynurenic acid clearance. In 14 healthy volunteers, it raised peak plasma concentrations about 3.3-fold compared with predose levels. This was a blood effect, not a measured 3.3-fold change in urine.
• Analytical conditions: LC-MS measurements can be affected by sample handling, calibration, and substances in urine that alter the instrument's signal. Laboratory validation and appropriate internal standards reduce these effects, but different assays and collection formats should not be assumed to produce interchangeable results.

What a Trend Can Show

Repeated measurements can document a change under comparable conditions. The size of change that represents a meaningful improvement in health has not been established, and a trend by itself cannot confirm that a diet, supplement, or treatment is working.